Summary
Global Markets Direct’s, ‘Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2016’, provides an overview of the Relapsed Acute Myeloid Leukemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Relapsed Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsed Acute Myeloid Leukemia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia
- The report reviews pipeline therapeutics for Relapsed Acute Myeloid Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Relapsed Acute Myeloid Leukemia therapeutics and enlists all their major and minor projects
- The report assesses Relapsed Acute Myeloid Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Relapsed Acute Myeloid Leukemia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG
AbbVie Inc.
Actinium Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Amgen Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
AVEO Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
BioLineRx, Ltd.
BioSight Ltd.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cellceutix Corporation
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
EpiZyme, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
FORMA Therapeutics, Inc.
Fujifilm Corporation
GlaxoSmithKline Plc
GlycoMimetics, Inc.
Igenica Biotherapeutics, Inc.
Incyte Corporation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Johnson & Johnson
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
MacroGenics, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
NantKwest, Inc.
Novartis AG
Oxford BioTherapeutics Ltd
Pfizer Inc.
Pharma Mar, S.A.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Sunesis Pharmaceuticals, Inc.
TaiGen Biotechnology Co., Ltd.
Tolero Pharmaceuticals, Inc.
Verastem, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Relapsed Acute Myeloid Leukemia Overview 10
Therapeutics Development 11
Pipeline Products for Relapsed Acute Myeloid Leukemia - Overview 11
Pipeline Products for Relapsed Acute Myeloid Leukemia - Comparative Analysis 12
Relapsed Acute Myeloid Leukemia - Therapeutics under Development by Companies 13
Relapsed Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 17
Relapsed Acute Myeloid Leukemia - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Relapsed Acute Myeloid Leukemia - Products under Development by Companies 21
Relapsed Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 26
Relapsed Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 27
4SC AG 27
AbbVie Inc. 28
Actinium Pharmaceuticals, Inc. 29
Agios Pharmaceuticals, Inc. 30
Amgen Inc. 31
Arog Pharmaceuticals, Inc. 32
Array BioPharma Inc. 33
Astellas Pharma Inc. 34
AVEO Pharmaceuticals, Inc. 35
Bellicum Pharmaceuticals, Inc. 36
BioLineRx, Ltd. 37
BioSight Ltd. 38
Boehringer Ingelheim GmbH 39
Boston Biomedical, Inc. 40
Bristol-Myers Squibb Company 41
Calithera Biosciences, Inc. 42
Celgene Corporation 43
Cellceutix Corporation 44
Cornerstone Pharmaceuticals, Inc. 45
CTI BioPharma Corp. 46
Daiichi Sankyo Company, Limited 47
Eisai Co., Ltd. 48
EpiZyme, Inc. 49
Exelixis, Inc. 50
F. Hoffmann-La Roche Ltd. 51
FORMA Therapeutics, Inc. 52
Fujifilm Corporation 53
GlaxoSmithKline Plc 54
GlycoMimetics, Inc. 55
Igenica Biotherapeutics, Inc. 56
Incyte Corporation 57
Jiangsu Hansoh Pharmaceutical Co., Ltd. 58
Johnson & Johnson 59
JW Pharmaceutical Corporation 60
Karyopharm Therapeutics, Inc. 61
Kyowa Hakko Kirin Co., Ltd. 62
Les Laboratoires Servier SAS 63
MacroGenics, Inc. 64
Merck & Co., Inc. 65
Millennium Pharmaceuticals, Inc. 66
NantKwest, Inc. 67
Novartis AG 68
Oxford BioTherapeutics Ltd 69
Pfizer Inc. 70
Pharma Mar, S.A. 71
Plexxikon Inc. 72
Polaris Pharmaceuticals, Inc. 73
Seattle Genetics, Inc. 74
Sunesis Pharmaceuticals, Inc. 75
TaiGen Biotechnology Co., Ltd. 76
Tolero Pharmaceuticals, Inc. 77
Verastem, Inc. 78
Relapsed Acute Myeloid Leukemia - Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Target 81
Assessment by Mechanism of Action 86
Assessment by Route of Administration 91
Assessment by Molecule Type 93
Drug Profiles 95
4SC-202 - Drug Profile 95
AG-120 - Drug Profile 97
AG-881 - Drug Profile 100
alvocidib hydrochloride - Drug Profile 101
AMG-232 - Drug Profile 103
AMG-330 - Drug Profile 104
aNK Program - Drug Profile 105
APTA-16 - Drug Profile 108
BI-836858 - Drug Profile 109
binimetinib - Drug Profile 110
BL-8040 - Drug Profile 115
bortezomib - Drug Profile 118
BPX-701 - Drug Profile 124
BST-236 - Drug Profile 126
buparlisib hydrochloride - Drug Profile 127
burixafor - Drug Profile 131
cabozantinib s-malate - Drug Profile 133
cafusertib hydrochloride - Drug Profile 138
CB-839 - Drug Profile 139
CC-90007 - Drug Profile 141
Cellular Immunotherapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia - Drug Profile 144
Cellular Immunotherapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia - Drug Profile 145
Cellular Immunotherapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 146
Cellular Immunotherapy to Target WT-1, NY-ESO-1, PRAME and Survivin for Oncology - Drug Profile 147
CPI-613 - Drug Profile 148
crenolanib besylate - Drug Profile 151
CWP-291 - Drug Profile 153
DFP-10917 - Drug Profile 155
DS-3032 - Drug Profile 156
E-6201 - Drug Profile 157
eltrombopag olamine - Drug Profile 159
erlotinib hydrochloride - Drug Profile 162
FF-10501 - Drug Profile 165
ficlatuzumab - Drug Profile 166
FLX-925 - Drug Profile 169
FT-1101 - Drug Profile 170
gedatolisib - Drug Profile 171
gilteritinib fumarate - Drug Profile 173
GMI-1271 - Drug Profile 174
GO-2032c - Drug Profile 176
GSK-2879552 - Drug Profile 177
GSK-525762 - Drug Profile 178
Hu8F4 - Drug Profile 179
HXR-9 - Drug Profile 180
IGN-523 - Drug Profile 181
imatinib mesylate - Drug Profile 183
indisulam - Drug Profile 186
Iomab-B - Drug Profile 188
JNJ-63709178 - Drug Profile 190
KHK-2823 - Drug Profile 191
KM-3174 - Drug Profile 192
lenalidomide - Drug Profile 196
lirilumab - Drug Profile 201
lurbinectedin - Drug Profile 203
MGD-006 - Drug Profile 207
MK-2206 - Drug Profile 208
napabucasin - Drug Profile 211
Oshadi D + Oshadi R - Drug Profile 214
OX-001 - Drug Profile 215
pegargiminase - Drug Profile 216
PIM-447 - Drug Profile 220
pinometostat - Drug Profile 221
PLX-51107 - Drug Profile 223
quizartinib dihydrochloride - Drug Profile 224
RG-6146 - Drug Profile 227
RG-7775 - Drug Profile 228
ruxolitinib phosphate - Drug Profile 229
S-055746 - Drug Profile 234
selinexor - Drug Profile 235
TAK-659 - Drug Profile 241
tigecycline - Drug Profile 242
tosedostat - Drug Profile 243
ulocuplumab - Drug Profile 246
vadastuximab talirine - Drug Profile 248
venetoclax - Drug Profile 250
vorinostat - Drug Profile 254
vosaroxin - Drug Profile 258
VS-4718 - Drug Profile 260
Relapsed Acute Myeloid Leukemia - Recent Pipeline Updates 261
Relapsed Acute Myeloid Leukemia - Dormant Projects 419
Relapsed Acute Myeloid Leukemia - Discontinued Products 421
Relapsed Acute Myeloid Leukemia - Product Development Milestones 422
Featured News & Press Releases 422
Appendix 431
Methodology 431
Coverage 431
Secondary Research 431
Primary Research 431
Expert Panel Validation 431
Contact Us 431
Disclaimer 432
List of Tables
Number of Products under Development for Relapsed Acute Myeloid Leukemia, H1 2016 17
Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Number of Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Development by Companies, H1 2016 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Comparative Analysis by Late Stage Development, H1 2016 24
Comparative Analysis by Clinical Stage Development, H1 2016 25
Comparative Analysis by Early Stage Development, H1 2016 26
Products under Development by Companies, H1 2016 27
Products under Development by Companies, H1 2016 (Contd..1) 28
Products under Development by Companies, H1 2016 (Contd..2) 29
Products under Development by Companies, H1 2016 (Contd..3) 30
Products under Development by Companies, H1 2016 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2016 32
Relapsed Acute Myeloid Leukemia - Pipeline by 4SC AG, H1 2016 33
Relapsed Acute Myeloid Leukemia - Pipeline by AbbVie Inc., H1 2016 34
Relapsed Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 35
Relapsed Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2016 36
Relapsed Acute Myeloid Leukemia - Pipeline by Amgen Inc., H1 2016 37
Relapsed Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 38
Relapsed Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H1 2016 39
Relapsed Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H1 2016 40
Relapsed Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 41
Relapsed Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 42
Relapsed Acute Myeloid Leukemia - Pipeline by BioLineRx, Ltd., H1 2016 43
Relapsed Acute Myeloid Leukemia - Pipeline by BioSight Ltd., H1 2016 44
Relapsed Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H1 2016 45
Relapsed Acute Myeloid Leukemia - Pipeline by Boston Biomedical, Inc., H1 2016 46
Relapsed Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2016 47
Relapsed Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H1 2016 48
Relapsed Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H1 2016 49
Relapsed Acute Myeloid Leukemia - Pipeline by Cellceutix Corporation, H1 2016 50
Relapsed Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 51
Relapsed Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H1 2016 52
Relapsed Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 53
Relapsed Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H1 2016 54
Relapsed Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H1 2016 55
Relapsed Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H1 2016 56
Relapsed Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 57
Relapsed Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics, Inc., H1 2016 58
Relapsed Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H1 2016 59
Relapsed Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H1 2016 60
Relapsed Acute Myeloid Leukemia - Pipeline by GlycoMimetics, Inc., H1 2016 61
Relapsed Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H1 2016 62
Relapsed Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H1 2016 63
Relapsed Acute Myeloid Leukemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016 64
Relapsed Acute Myeloid Leukemia - Pipeline by Johnson & Johnson, H1 2016 65
Relapsed Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H1 2016 66
Relapsed Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 67
Relapsed Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 68
Relapsed Acute Myeloid Leukemia - Pipeline by Les Laboratoires Servier SAS, H1 2016 69
Relapsed Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H1 2016 70
Relapsed Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H1 2016 71
Relapsed Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 72
Relapsed Acute Myeloid Leukemia - Pipeline by NantKwest, Inc., H1 2016 73
Relapsed Acute Myeloid Leukemia - Pipeline by Novartis AG, H1 2016 74
Relapsed Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H1 2016 75
Relapsed Acute Myeloid Leukemia - Pipeline by Pfizer Inc., H1 2016 76
Relapsed Acute Myeloid Leukemia - Pipeline by Pharma Mar, S.A., H1 2016 77
Relapsed Acute Myeloid Leukemia - Pipeline by Plexxikon Inc., H1 2016 78
Relapsed Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 79
Relapsed Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H1 2016 80
Relapsed Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016 81
Relapsed Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 82
Relapsed Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 83
Relapsed Acute Myeloid Leukemia - Pipeline by Verastem, Inc., H1 2016 84
Assessment by Monotherapy Products, H1 2016 85
Assessment by Combination Products, H1 2016 86
Number of Products by Stage and Target, H1 2016 88
Number of Products by Stage and Mechanism of Action, H1 2016 93
Number of Products by Stage and Route of Administration, H1 2016 98
Number of Products by Stage and Molecule Type, H1 2016 100
Relapsed Acute Myeloid Leukemia Therapeutics - Recent Pipeline Updates, H1 2016 267
Relapsed Acute Myeloid Leukemia - Dormant Projects, H1 2016 425
Relapsed Acute Myeloid Leukemia - Dormant Projects (Contd..1), H1 2016 426
Relapsed Acute Myeloid Leukemia - Discontinued Products, H1 2016 427
List of Figures
Number of Products under Development for Relapsed Acute Myeloid Leukemia, H1 2016 17
Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Comparative Analysis by Late Stage Development, H1 2016 24
Comparative Analysis by Clinical Stage Development, H1 2016 25
Comparative Analysis by Early Stage Products, H1 2016 26
Assessment by Monotherapy Products, H1 2016 85
Number of Products by Top 10 Targets, H1 2016 87
Number of Products by Stage and Top 10 Targets, H1 2016 87
Number of Products by Top 10 Mechanism of Actions, H1 2016 92
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 92
Number of Products by Routes of Administration, H1 2016 97
Number of Products by Stage and Routes of Administration, H1 2016 97
Number of Products by Molecule Types, H1 2016 99
Number of Products by Stage and Molecule Types, H1 2016 99
